NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 270 filers reported holding NOVOCURE LTD in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $250 | -20.4% | 6,029 | +15.5% | 0.00% | -50.0% |
| Q1 2023 | $314 | -15.4% | 5,222 | +3.3% | 0.00% | 0.0% |
| Q4 2022 | $371 | -99.9% | 5,057 | -5.8% | 0.00% | 0.0% |
| Q3 2022 | $408,000 | +8.8% | 5,369 | -0.4% | 0.00% | 0.0% |
| Q2 2022 | $375,000 | -20.2% | 5,393 | -5.0% | 0.00% | 0.0% |
| Q1 2022 | $470,000 | +8.8% | 5,676 | -1.4% | 0.00% | 0.0% |
| Q4 2021 | $432,000 | -34.4% | 5,754 | +1.5% | 0.00% | -33.3% |
| Q3 2021 | $659,000 | -47.9% | 5,670 | -0.5% | 0.00% | -50.0% |
| Q2 2021 | $1,264,000 | +54.0% | 5,700 | -8.3% | 0.01% | +50.0% |
| Q1 2021 | $821,000 | -26.4% | 6,214 | -3.5% | 0.00% | -42.9% |
| Q4 2020 | $1,115,000 | +40.4% | 6,441 | -9.7% | 0.01% | +40.0% |
| Q3 2020 | $794,000 | +100.5% | 7,134 | +6.7% | 0.01% | +66.7% |
| Q2 2020 | $396,000 | -6.2% | 6,685 | +6.7% | 0.00% | -25.0% |
| Q1 2020 | $422,000 | +88.4% | 6,268 | +135.6% | 0.00% | +100.0% |
| Q4 2019 | $224,000 | – | 2,660 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |